NFL BIOSCIENCES
Company Management

NFL BIOSCIENCES

Research Paris, Fr 7 employees
Employees
7

NFL BIOSCIENCES Overview

Headquarters
Paris, Fr
Industry
Research
Employees
7
Founded
2009
Funding
1.4M

About NFL BIOSCIENCES

NFL BIOSCIENCES clinically develops NFL-101, a patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit. It is delivered via two simple subcutaneous injections, administered one week apart, making patient compliance a breeze. There exists vast anecdotal evidence, from more than 10,000 smokers treated off-label in France with a predecessor product developed by the Pasteur Institute, that NFL-101 is safe and efficacious for total smoking cessation at twelve months. A Phase 1 clinical trial that reported data in 2017 confirmed safety and efficacy in smokers willing and trying to quit, in terms of total cessation at twelve months as well as reduction without compensatory over-smoking.

NFL BIOSCIENCES Contact Details

People in AeroLeads
4

NFL BIOSCIENCES Org Chart

Sample employees and titles
Name Title Contact
Bruno Lafont Co-founder and CEO at Nfl Biosciences
View
Guillaume Audema Financial Director Chez Nfl Biosciences
View
Darshana Dhar Retired at Nfl Biosciences
View
Maaz Malik Working in National Food Company
View

Employees by Management Level

Individual contributor 2 profiles
Executive 1 profile
Director 1 profile

Compare Similar Companies to NFL BIOSCIENCES